Cilaprime T 10/40mg Tablet 10s

Cilaprime T 10/40mg Tablet 10s is a fixed-dose combination medicine used in the treatment of hypertension (or high blood pressure). It combines two active ingredients, Cilnidipine and Telmisartan, which work through different but complementary mechanisms to provide effective and sustained blood pressure control. This dual approach not only helps reduce elevated blood pressure but also lowers the risk of serious cardiovascular complications such as stroke, heart attack, and kidney damage.

Cilnidipine is a calcium channel blocker that acts on both L-type and N-type calcium channels. By inhibiting calcium influx into vascular smooth muscle, it relaxes and widens blood vessels, thereby reducing vascular resistance. Its additional action on N-type channels helps suppress excessive sympathetic nerve activity, which further contributes to lowering blood pressure and reducing strain on the heart. This unique dual-channel blockade makes Cilnidipine more effective than traditional calcium channel blockers in controlling blood pressure without causing reflex tachycardia.

Telmisartan belongs to the class of angiotensin II receptor blockers (ARBs). It works by selectively blocking the angiotensin II type 1 (AT1) receptors, preventing angiotensin II from exerting its vasoconstrictive and aldosterone-secreting effects. As a result, blood vessels remain relaxed and sodium and water retention is minimised, leading to a sustained reduction in blood pressure. Telmisartan is also known for its long half-life, which ensures 24-hour coverage with once-daily dosing, improving patient compliance and convenience.

Together, Cilnidipine and Telmisartan provide a synergistic effect by targeting two major pathways involved in blood pressure regulation: vascular smooth muscle contraction and the renin-angiotensin system. This combination therapy is particularly beneficial for patients who require more than one agent to achieve optimal blood pressure control. It not only reduces systolic and diastolic blood pressure effectively but also offers protection to vital organs such as the heart, brain, and kidneys, which are often affected by long-standing hypertension.

Cilaprime T 10/40mg Tablet 10s is indicated for:

When single medicines are insufficient:

For patients whose blood pressure is not adequately controlled with either telmisartan or cilnidipine alone.

Initial combination therapy:

In patients with significantly elevated blood pressure (such as stage 2 hypertension) where starting with two medicines may be necessary to achieve target levels.

Reducing cardiovascular risk:

By controlling blood pressure, it helps lower the risk of stroke, heart attack, and other complications related to chronic hypertension.

Superior Blood Pressure Control:

The complementary mechanisms (RAAS blockade via Telmisartan and Dual CCB action via Cilnidipine) provide greater efficacy and sustained blood pressure lowering.

Reduced Peripheral Oedema Risk:

The unique N-type calcium channel blocking action of Cilnidipine offers sympathoinhibition, potentially reducing the ankle swelling (oedema) commonly associated with other L-type CCBs.

Cardiorenal Protection:

Telmisartan, as an ARB, provides protective effects for the kidneys and heart beyond simple blood pressure reduction.

Convenience and Compliance:

Fixed-dose combination (FDC) therapy simplifies the regimen to a single, once-daily dose, which greatly improves patient adherence compared to taking two separate medications.

When taken as directed, Cilaprime T 10/40mg Tablet 10s is generally safe. Side effects are usually rare, mild, and temporary.

Common Side Effects (Rare):

• Nausea and Vomiting
• Constipation
• Slight drowsiness or fatigue
• Dizziness or Lightheadedness (Symptomatic Hypotension)
• Back pain
• Peripheral Oedema (Swelling of ankles/feet - less common than with standard CCBs).

Serious Side Effects (Stop taking the medicine and seek urgent medical attention if you experience):

• Severe Allergic Reaction (Angioedema): Rash, swelling of the face, throat, or tongue, difficulty breathing, or dizziness.
• Serious Skin Reactions (Very Rare): Redness, blistering, peeling of the skin (e.g., Stevens-Johnson Syndrome).
• Signs of Liver Damage: Yellowing of the skin or eyes (jaundice), persistent nausea, unexplained fatigue, or pain in the upper right abdomen.
• Signs of Severe Hypotension: Profound lightheadedness, fainting, or inability to stand.
• Hyperkalemia: Unusually high potassium levels (may cause muscle weakness or irregular heartbeat).

• Dosage: The dose will be determined by your physician based on your response to the individual components. The maintenance dose for this combination is typically one [DOSAGE_FORM_TYPE] of [STRENGTH] once daily.

• Administration: The [DOSAGE_FORM_TYPE] should be swallowed whole, with or without food, once daily. It is critical to take the medicine at approximately the same time each day to maintain stable blood pressure control.

• Crucial Consistency: Do not stop or adjust the dosage without consulting your prescribing physician, even if you feel well. Sudden cessation can lead to a dangerous increase in blood pressure (rebound hypertension).

Cilaprime T 10/40mg Tablet 10s lowers blood pressure by combining two medicines that act through different but complementary pathways.

• Cilnidipine is a calcium channel blocker that relaxes blood vessels by blocking L-type calcium channels in the smooth muscle of the vessel walls, allowing the arteries to widen and reducing resistance to blood flow. In addition, cilnidipine blocks N-type calcium channels on sympathetic nerve endings, which reduces the release of norepinephrine. This helps limit excessive sympathetic activity, lowering the risk of reflex increases in heart rate and reducing fluid-related side effects such as ankle swelling.
• Telmisartan is an angiotensin II receptor blocker that inhibits the action of angiotensin II, a hormone involved in the renin-angiotensin-aldosterone system (RAAS). By blocking this pathway, telmisartan prevents blood vessel constriction and reduces aldosterone-mediated salt and water retention, leading to sustained blood vessel relaxation and lower blood pressure.

Together, cilnidipine and telmisartan provide effective and sustained blood pressure reduction by relaxing blood vessels, lowering vascular resistance, and reducing strain on the heart, while maintaining good tolerability for long-term use.

• Take your tablet once a day, at the same time, to keep your blood pressure under control.
• Do not stop taking the medicine suddenly, even if you feel fine. High blood pressure often has no symptoms, but stopping treatment can be dangerous.
• Eat less salt, follow a healthy diet, exercise regularly, and avoid smoking or drinking too much alcohol. These habits make the medicine work better.
• Check your blood pressure often at home or during doctor visits. This helps you and your doctor know if the medicine is working.
• You may feel dizzy, lightheaded, or notice mild swelling in your ankles. These are common side effects. If you feel very unwell, faint, or notice swelling of your face or lips, seek medical help immediately.
• Tell your doctor about all other medicines you are taking. Some medicines may interact with this one.
• This medicine is not safe during pregnancy or breastfeeding. If you are pregnant, planning pregnancy, or nursing, talk to your doctor right away.

Store the medication in the original packaging at room temperature (typically below 30 °C / 86 °F), away from moisture, heat, and direct light. Do not crush, divide, or chew the [DOSAGE_FORM_TYPE] unless instructed by your doctor. Keep the medication out of the reach of children.

• Potassium-Rich Foods: Caution is advised. Due to the risk of hyperkalemia (high potassium) from Telmisartan, large quantities of potassium-rich foods (e.g., bananas, spinach, citrus juices, potassium-containing salt substitutes) should be consumed only with medical guidance.
• Grapefruit Juice: Caution is advised. Grapefruit juice may theoretically inhibit the metabolism of Cilnidipine, potentially increasing its concentration in the blood and enhancing its blood pressure-lowering effect and side effects.

• Aliskiren (in Diabetic or Renally Impaired Patients): CONTRAINDICATED. Dual blockade of the RAAS system with an ARB (Telmisartan) and a direct renin inhibitor (Aliskiren) increases the risk of severe hypotension, hyperkalemia, and renal impairment.
• ACE Inhibitors and Other ARBs: Should not be co-administered due to increased risk of hypotension, hyperkalemia, and renal dysfunction.
• Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride) and Potassium Supplements: Increases the risk of severe hyperkalemia (high potassium). Frequent monitoring of potassium levels is essential.
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) and COX-2 Inhibitors: Concurrent use, especially in elderly or volume-depleted patients, may worsen kidney function (including possible acute renal failure) and reduce the antihypertensive effect.
• Digoxin: Telmisartan may increase plasma levels of Digoxin. Monitor Digoxin levels upon initiation or dose change.
• Other Antihypertensive Agents: Concurrent use with other drugs that lower blood pressure (e.g., beta-blockers, diuretics) may result in an additive hypotensive effect.

• Angioedema History: CONTRAINDICATED in patients with a history of angioedema related to previous ARB or ACE inhibitor use.
• Severe Renal Impairment: Requires dose adjustment and frequent monitoring.
• Hepatic Impairment: Requires dose adjustment and careful monitoring.
• Bilateral Renal Artery Stenosis: Should be used with extreme caution or avoided, as RAAS inhibitors can precipitate acute renal failure in these patients.

The usual daily dose of Cilaprime T 10/40mg Tablet 10s is one tablet taken once daily, as prescribed by the doctor. The exact strength used depends on the individual patient’s blood pressure levels, response to treatment, and any other medical conditions.

Cilaprime T 10/40mg Tablet 10s should be taken at the same time each day, with or without food. Dose adjustments, if needed, should only be made by a healthcare professional based on blood pressure control and tolerability.

The most likely manifestations of overdose are severe hypotension (profoundly low blood pressure), accompanied by dizziness, syncope (fainting), and possibly hyperkalemia. Action Required: If an overdose is suspected, immediately seek emergency medical assistance. Management typically involves supportive care, including lying the patient down with legs elevated, and potentially IV fluid administration to counteract severe hypotension.

If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next scheduled dose (e.g., within 12 hours), skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to make up for the missed one.